Effect of interleukin-8 receptor B (IL8RB) rs1126579 C>T variation on the risk to cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249.
   PubMed Web of Science ®Google Scholar
• Miller KD, Fidler-Benaoudia M, Keegan TH, et al. Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin. 2020;70:443–459.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
   PubMed Web of Science ®Google Scholar
• Roder DM, Warr A, Patterson P, et al. Australian adolescents and young adults-trends in cancer incidence, mortality, and survival over three decades. J Adolesc Young Adult Oncol. 2018;7:326–338.
   PubMed Web of Science ®Google Scholar
• Wang X, Guo J, Yu P, et al. The roles of extracellular vesicles in the development, microenvironment, anticancer drug resistance, and therapy of head and neck squamous cell carcinoma. J Exp Clin Cancer Res. 2021;40:35.
   PubMed Web of Science ®Google Scholar
• Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;100:1672–1694.
   PubMed Web of Science ®Google Scholar
• Vinader V, Afarinkia K. The emerging role of CXC chemokines and their receptors in cancer. Future Med Chem. 2012;4:853–867.
   PubMed Web of Science ®Google Scholar
• Bie Y, Ge W, Yang Z, et al. The crucial role of CXCL8 and its receptors in colorectal liver metastasis. Dis Markers. 2019;2019:8023460.
   PubMed Web of Science ®Google Scholar
• Mollica Poeta V, Massara M, Capucetti A, et al. Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front Immunol. 2019;10:379.
   PubMed Web of Science ®Google Scholar
• Raffaghello L, Cocco C, Corrias MV, et al. Chemokines in neuroectodermal tumour progression and metastasis. Seminars in cancer biology 2009; 19:97–102.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Aparicio M, Alfaro C. Influence of Interleukin-8 and Neutrophil Extracellular Trap (NET) formation in the tumor microenvironment: is there a pathogenic role? J Immunol Res. 2019;2019:6252138.
   PubMed Web of Science ®Google Scholar
• Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angiogenesis. J Leukoc Biol. 2000;68:1–8.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Ma XL, Wei YQ, et al. Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases. Biochim Biophys Acta. 2019;1871:289–312.
   PubMed Web of Science ®Google Scholar
• Feniger-Barish R, Belkin D, Zaslaver A, et al. GCP-2-induced internalization of IL-8 receptors: hierarchical relationships between GCP-2 and other ELR(+)-CXC chemokines and mechanisms regulating CXCR2 internalization and recycling. Blood. 2000;95(5):1551–1559.
   PubMed Web of Science ®Google Scholar
• Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14:6735–6741.
   PubMed Web of Science ®Google Scholar
• Keeley EC, Mehrad B, Strieter RM. CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res. 2010;106:91–111.
   PubMed Web of Science ®Google Scholar
• Donahue TR, Hines OJ. CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer. World J Surg. 2009;33:710–715.
   PubMed Web of Science ®Google Scholar
• Liu Q, Li A, Tian Y, et al. The CXCL8-CXCR1/2 pathways in cancer. Cytokine Growth Factor Rev. 2016;31:61–71.
   PubMed Web of Science ®Google Scholar
• Matsuo Y, Takeyama H, Guha S. Cytokine network: new targeted therapy for pancreatic cancer. Curr Pharm Des. 2012;18:2416–2419.
   PubMed Web of Science ®Google Scholar
• Li L, Xu L, Yan J, et al. CXCR2-CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2015;34:129.
   PubMed Web of Science ®Google Scholar
• Pączek S, Łukaszewicz-Zając M, Gryko M, et al. The Clinical Utility of Serum CXCR-2 Assessment in Colorectal Cancer (CRC) Patients. Anticancer Res. 2021;41:1421–1428.
   PubMed Web of Science ®Google Scholar
• Presti M, Mazzon E, Basile MS, et al. Overexpression of macrophage migration inhibitory factor and functionally-related genes, D-DT, CD74, CD44, CXCR2 and CXCR4, in glioblastoma. Oncol Lett. 2018;16:2881–2886.
   PubMed Web of Science ®Google Scholar
• Strieter RM, Polverini PJ, Arenberg DA, et al. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J Leukoc Biol. 1995;57:752–762.
   PubMed Web of Science ®Google Scholar
• Imafuji H, Matsuo Y, Ueda G, et al. Acquisition of gemcitabine resistance enhances angiogenesis via upregulation of IL‑8 production in pancreatic cancer. Oncol Rep. 2019;41:3508–3516.
   PubMed Web of Science ®Google Scholar
• Payne AS, Cornelius LA. The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol. 2002;118:915–922.
   PubMed Web of Science ®Google Scholar
• An H, Xu L, Chang Y, et al. CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma. Eur J Cancer. 2015;51:1953–1961
   PubMed Web of Science ®Google Scholar
• Nishi T, Takeuchi H, Matsuda S, et al. CXCR2 expression and postoperative complications affect long-term survival in patients with esophageal cancer. World J Surg Oncol. 2015;13:232.
   PubMed Web of Science ®Google Scholar
• Maeda S, Kuboki S, Nojima H, et al. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma. Cytokine. 2017;95:12–21.
   PubMed Web of Science ®Google Scholar
• Savage SA, Abnet CC, Mark SD, et al. Variants of the IL8 and IL8RB genes and risk for gastric cardia adenocarcinoma and esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2004;13:2251–2257.
   PubMed Web of Science ®Google Scholar
• Brown EE, Fallin D, Ruczinski I, et al. Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity. Cancer Epidemiol Biomarkers Prev. 2006;15:926–934.
   PubMed Web of Science ®Google Scholar
• Kamangar F, Abnet CC, Hutchinson AA, et al. Polymorphisms in inflammation-related genes and risk of gastric cancer (Finland). Cancer Causes Control. 2006;17:117–125.
   PubMed Web of Science ®Google Scholar
• Lee KM, Shen M, Chapman RS, et al. Polymorphisms in immunoregulatory genes, smoky coal exposure and lung cancer risk in Xuan Wei, China. Carcinogenesis. 2007;28:1437–1441.
   PubMed Web of Science ®Google Scholar
• Andrew AS, Gui J, Sanderson AC, et al. Bladder cancer SNP panel predicts susceptibility and survival. Hum Genet. 2009;125:527–539.
   PubMed Web of Science ®Google Scholar
• Snoussi K, Mahfoudh W, Bouaouina N, et al. Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness. BMC Cancer. 2010;10:283.
   PubMed Web of Science ®Google Scholar
• Bondurant KL, Lundgreen A, Herrick JS, et al. Interleukin genes and associations with colon and rectal cancer risk and overall survival. Int J Cancer. 2013;132:905–915.
   PubMed Web of Science ®Google Scholar
• Singh V, Jaiswal PK, Kapoor R, et al. Impact of chemokines CCR5∆32, CXCL12G801A, and CXCR2C1208T on bladder cancer susceptibility in north Indian population. Tumour Biol. 2014;35:4765–4772.
   PubMedGoogle Scholar
• Ryan BM, Robles AI, McClary AC, et al. Identification of a functional SNP in the 3ʹUTR of CXCR2 that is associated with reduced risk of lung cancer. Cancer Res. 2015;75:566–575.
   PubMed Web of Science ®Google Scholar
• Franz JM, Portela P, Salim PH, et al. CXCR2 +1208 CT genotype may predict earlier clinical stage at diagnosis in patients with prostate cancer. Cytokine. 2017;97:193–200.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45:139–145.
   PubMed Web of Science ®Google Scholar
• Ng KH, Peh WC. Presenting the statistical results. Singapore Med J. 2009;50:11–14.
   PubMed Web of Science ®Google Scholar
• Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267–273.
   PubMed Web of Science ®Google Scholar
• Sun W, Shi H, Yuan Z, et al. Prognostic Value of Genes and Immune Infiltration in Prostate Tumor Microenvironment. Front Oncol. 2020;10:584055.
   PubMed Web of Science ®Google Scholar
• Pan HY, Mi YY, Xu K, et al. Association of C-reactive protein (CRP) rs1205 and rs2808630 variants and risk of cancer. J Cell Physiol. 2020;235:8571–8584.
   PubMed Web of Science ®Google Scholar
• Zhang LF, Xu K, Tang BW, et al. Association between SOD2 V16A variant and urological cancer risk. Aging (Albany NY). 2020;12:825–843.
   PubMedGoogle Scholar
• Gabellini C, Trisciuoglio D, Desideri M, et al. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. Eur J Cancer. 2009;45:2618–2627.
   PubMed Web of Science ®Google Scholar
• Kemp DM, Pidich A, Larijani M, et al. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment. Oncotarget. 2017;8:14428–14442.
   PubMedGoogle Scholar
• Yang Y, Luo B, An Y, et al. Systematic review and meta-analysis of the prognostic value of CXCR2 in solid tumor patients. Oncotarget. 2017;8:109740–109751.
   PubMedGoogle Scholar
• Qiao B, Luo W, Liu Y, et al. The prognostic value of CXC chemokine receptor 2 (CXCR2) in cancers: a meta-analysis. Oncotarget. 2018;9:15068–15076.
   PubMedGoogle Scholar
• Wu H, Zhang Z, Xiao XY, et al. Toll-like receptor 2 (TLR2) is a candidate prognostic factor in testicular germ cell tumors as well as an indicator of immune function in the tumor microenvironment. Bioengineered. 2021;12:1939–1951.
   PubMed Web of Science ®Google Scholar
• Wu H, Zhang ZY, Zhang Z, et al. Prediction of bladder cancer outcome by identifying and validating a mutation-derived genomic instability-associated long noncoding RNA (lncRNA) signature. Bioengineered. 2021;12:1725–1738.
   PubMed Web of Science ®Google Scholar